BioRestorative Therapies, Inc. (BRTX)
NASDAQ: BRTX · Real-Time Price · USD
1.610
+0.060 (3.87%)
May 22, 2025, 12:34 PM - Market open
BioRestorative Therapies Employees
BioRestorative Therapies had 11 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
11
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$35,545
Profits / Employee
-$1,099,630
Market Cap
12.08M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BRTX News
- 7 days ago - BioRestorative Therapies, Inc. (BRTX) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 9 days ago - Phase 2 Trial of BRTX-100 in cLDD Continues to Generate Positive Preliminary Blinded Data - GlobeNewsWire
- 13 days ago - BioRestorative Therapies to Report First Quarter 2025 Financial Results and Host Conference Call on May 14, 2025 - GlobeNewsWire
- 15 days ago - BioRestorative to Present a BRTX-100 Clinical Update at ISCT 2025 - GlobeNewsWire
- 5 weeks ago - BioRestorative to Participate in Benzinga All-Access Show Today to Discuss Recent Achievements of Key Clinical & Regulatory Milestones, and Highlight Commercial Opportunities - GlobeNewsWire
- 6 weeks ago - BioRestorative Confirms No Material Impact from Reciprocal Tariffs; All BRTX-100 Production & Manufacturing Performed in the United States - GlobeNewsWire
- 7 weeks ago - BioRestorative Therapies, Inc. (BRTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioRestorative Announces FDA Clearance of IND for Phase 2 Trial of BRTX-100 in Chronic Cervical Discogenic Pain - GlobeNewsWire